Andrew R Zullo1,2,3,4, Uvette Lou5, Sarah E Cabral1, Justin Huynh1, Christine M Berard-Collins1. 1. 1 Department of Pharmacy, Rhode Island Hospital, Providence, RI, USA. 2. 2 Department of Health Services, Policy, and Practice, Brown University, Providence, RI, USA. 3. 3 Department of Epidemiology, Brown University, Providence, RI, USA. 4. 4 Providence Veterans Affairs Medical Center, Center of Innovation in Long-Term Services and Supports, Providence, RI, USA. 5. 5 Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Abstract
INTRODUCTION: Guidelines recommend pegfilgrastim for primary prophylaxis of febrile neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines could result in overuse and increased costs, underuse is also a concern and could compromise quality of care. Our objectives were to evaluate guideline adherence and quantify the extent to which physician heterogeneity may influence pegfilgrastim use. METHODS: We randomly sampled 550 patients from a retrospective cohort of those who received infusions at an academic cancer center between 1 September 2013 and 1 September 2014. Electronic medical and drug dispensing records provided information on patient characteristics, chemotherapy characteristics, prescribing physician, and pegfilgrastim administration. RESULTS: We included 154 patients treated by 25 physicians. About half of patients were male and mean age was 61.3 years. Forty (26.1%) patients had no febrile neutropenia risk factors, 62 (40.5%) had one, and 51 (33.3%) had two or more. Thirty patients (19.5%) received pegfilgrastim, of which 12 (40%) received palliative chemotherapy. Nine (60%) of 15 patients on a regimen with a febrile neutropenia risk ≥ 20% received pegfilgrastim. Pegfilgrastim use significantly varied by cancer type (p < 0.01), chemotherapy regimen (p < 0.001), and regimen febrile neutropenia risk (p < 0.001). Multivariable analysis reaffirmed the association between chemotherapy regimen febrile neutropenia risk ≥ 20% and pegfilgrastim use (odds ratio (OR) = 10.1, 95% confidence interval (CI): 1.6-62.7) and suggested that 31% (95% CI: 8%-71%) of the variation in use was attributable to physician characteristics. CONCLUSION: Pegfilgrastim was potentially overused for palliative chemotherapy and underused for chemotherapy regimens with febrile neutropenia risk ≥ 20%. Successful interventions to modify prescribing practices likely require an understanding of the relationship between specific physician characteristics and pegfilgrastim use.
INTRODUCTION: Guidelines recommend pegfilgrastim for primary prophylaxis of febrile neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines could result in overuse and increased costs, underuse is also a concern and could compromise quality of care. Our objectives were to evaluate guideline adherence and quantify the extent to which physician heterogeneity may influence pegfilgrastim use. METHODS: We randomly sampled 550 patients from a retrospective cohort of those who received infusions at an academic cancer center between 1 September 2013 and 1 September 2014. Electronic medical and drug dispensing records provided information on patient characteristics, chemotherapy characteristics, prescribing physician, and pegfilgrastim administration. RESULTS: We included 154 patients treated by 25 physicians. About half of patients were male and mean age was 61.3 years. Forty (26.1%) patients had no febrile neutropenia risk factors, 62 (40.5%) had one, and 51 (33.3%) had two or more. Thirty patients (19.5%) received pegfilgrastim, of which 12 (40%) received palliative chemotherapy. Nine (60%) of 15 patients on a regimen with a febrile neutropenia risk ≥ 20% received pegfilgrastim. Pegfilgrastim use significantly varied by cancer type (p < 0.01), chemotherapy regimen (p < 0.001), and regimen febrile neutropenia risk (p < 0.001). Multivariable analysis reaffirmed the association between chemotherapy regimen febrile neutropenia risk ≥ 20% and pegfilgrastim use (odds ratio (OR) = 10.1, 95% confidence interval (CI): 1.6-62.7) and suggested that 31% (95% CI: 8%-71%) of the variation in use was attributable to physician characteristics. CONCLUSION: Pegfilgrastim was potentially overused for palliative chemotherapy and underused for chemotherapy regimens with febrile neutropenia risk ≥ 20%. Successful interventions to modify prescribing practices likely require an understanding of the relationship between specific physician characteristics and pegfilgrastim use.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski Journal: Eur J Cancer Date: 2010-11-20 Impact factor: 9.162
Authors: Lillian Sung; Paul C Nathan; Shabbir M H Alibhai; George A Tomlinson; Joseph Beyene Journal: Ann Intern Med Date: 2007-09-18 Impact factor: 25.391
Authors: Jeffrey Crawford; James Armitage; Lodovico Balducci; Pamela Sue Becker; Douglas W Blayney; Spero R Cataland; Mark L Heaney; Susan Hudock; Dwight D Kloth; David J Kuter; Gary H Lyman; Brandon McMahon; Hope S Rugo; Ayman A Saad; Lee S Schwartzberg; Sepideh Shayani; David P Steensma; Mahsa Talbott; Saroj Vadhan-Raj; Peter Westervelt; Michael Westmoreland; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-10-01 Impact factor: 11.908
Authors: John Kenna; Leana Mahmoud; Andrew R Zullo; N Stevenson Potter; Corey R Fehnel; Bradford B Thompson; Linda C Wendell Journal: Nutr Clin Pract Date: 2015-12-16 Impact factor: 3.080
Authors: Laura Hunt McAuliffe; Andrew R Zullo; Ruth Dapaah-Afriyie; Christine Berard-Collins Journal: Am J Health Syst Pharm Date: 2018-02-01 Impact factor: 2.980
Authors: Mikko S Venäläinen; Eetu Heervä; Outi Hirvonen; Sohrab Saraei; Tomi Suomi; Toni Mikkola; Maarit Bärlund; Sirkku Jyrkkiö; Tarja Laitinen; Laura L Elo Journal: Cancer Med Date: 2021-12-03 Impact factor: 4.452